Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
19 hedge funds and large institutions have $12M invested in Bellerophon Therapeutics, Inc. in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
9.09% less ownership
Funds ownership: 50.4% → 41.31% (-9.1%)
17% less funds holding
Funds holding: 23 → 19 (-4)
28% less capital invested
Capital invested by funds: $16.7M → $12M (-$4.77M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$51.5K |
| 2 |
VF
Virtu Financial
New York
|
+$16.1K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$10.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.3K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$426 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management II
New York
|
-$1.48M |
| 2 |
VMI
VHCP Management III
New York
|
-$862K |
| 3 |
AC
Armistice Capital
New York
|
-$427K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$40K |
| 5 |
Millennium Management
New York
|
-$17K |
BLPH Hedge Fund Activity: Q4 2019 in Review
19 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2019, worth a combined $12M — down 28% from $16.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BLPH and 3 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $51.5K. The largest seller was VHCP Management II, cutting an estimated $1.48M.
- 19 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2019, down from 23 in Q3 2019.
- Funds reported $12M of Bellerophon Therapeutics, Inc. stock for Q4 2019, down 28% quarter-over-quarter.
- 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2019 and 7 closed out, a net change of -4 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q4 2019 was Renaissance Technologies, an estimated $51.5K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q4 2019 was VHCP Management II, an estimated $1.48M sold.
Based on aggregated 13F filings for Q4 2019.